Cancers (May 2023)

Preclinical Models of Adrenocortical Cancer

  • Andrew J. H. Sedlack,
  • Samual J. Hatfield,
  • Suresh Kumar,
  • Yasuhiro Arakawa,
  • Nitin Roper,
  • Nai-Yun Sun,
  • Naris Nilubol,
  • Katja Kiseljak-Vassiliades,
  • Chuong D. Hoang,
  • Emily K. Bergsland,
  • Jonathan M. Hernandez,
  • Yves Pommier,
  • Jaydira del Rivero

DOI
https://doi.org/10.3390/cancers15112873
Journal volume & issue
Vol. 15, no. 11
p. 2873

Abstract

Read online

Adrenocortical cancer is an aggressive endocrine malignancy with an incidence of 0.72 to 1.02 per million people/year, and a very poor prognosis with a five-year survival rate of 22%. As an orphan disease, clinical data are scarce, meaning that drug development and mechanistic research depend especially on preclinical models. While a single human ACC cell line was available for the last three decades, over the last five years, many new in vitro and in vivo preclinical models have been generated. Herein, we review both in vitro (cell lines, spheroids, and organoids) and in vivo (xenograft and genetically engineered mouse) models. Striking leaps have been made in terms of the preclinical models of ACC, and there are now several modern models available publicly and in repositories for research in this area.

Keywords